Summary Sobi presented new clinical and real-world evidence across four rare hematology franchises at EHA 2026: PNH (pegcetacoplan), ITP (avatrombopag), HLH (emapalumab), and myelofibrosis (pacritinib). While no pivotal efficacy readouts were disclosed, the package reinforces the commercial durability and clinical…
Summary Johnson & Johnson presented pivotal ENERGY Phase 2/3 data showing statistically significant durable hemoglobin responses for IMAAVY in warm autoimmune hemolytic anemia, supporting its February 2026 sBLA filing. What Happened Patients receiving IMAAVY achieved durable hemoglobin responses at roughly…
Summary Climb Bio presented the first clinical data for budoprutug, an anti-CD19 monoclonal antibody, in primary immune thrombocytopenia (ITP). Early Phase 1b results demonstrated robust B-cell depletion, encouraging safety, and meaningful platelet responses in heavily pretreated patients, introducing a new…
Summary SonoThera closed an oversubscribed $125M Series B financing to advance DMD and ADPKD programs toward the clinic, validating its non-viral genetic medicine delivery platform. What Happened Vida Ventures led the round with participation from ARK Invest, Otsuka, UCB Ventures,…
Summary GSK agreed to acquire Nuvalent for approximately $10.6 billion, one of the largest biotech acquisitions of 2026. The transaction adds late-stage ROS1 and ALK targeted oncology assets and significantly accelerates GSK’s effort to rebuild a leading precision oncology franchise.…
Summary Parabilis, formerly FogPharma, increased its planned IPO size to as much as $636.8 million, potentially becoming one of the largest biotech IPOs in recent years. The financing represents a major validation event for the company’s Helicon peptide platform and…
Summary Incyte agreed to acquire Vega Therapeutics for up to $2.0 billion, adding Phase 3 asset VGA039, a first-in-class Protein S-modulating antibody for von Willebrand disease. The deal represents Incyte’s most significant strategic move beyond the Jakafi franchise and positions…
Summary Nurix and Roche announced a global collaboration for bexobrutideg, a potential best-in-class BTK degrader across hematology and immunology. What Happened Roche will co-develop and co-commercialize bexobrutideg, an oral degrader that eliminates BTK protein rather than inhibiting it. Deep Analysis…
Summary AbbVie will present 21 abstracts at EHA 2026 spanning multiple myeloma, DLBCL, follicular lymphoma, CLL, AML, and AL amyloidosis. The most important readout is etentamig (ABBV-383) in patients previously exposed to BCMA-directed therapies, a setting with significant unmet need…
Summary Eli Lilly signed a collaboration with Ascidian worth up to $1.9B to develop in vivo RNA exon-editing therapies for inherited kidney diseases, validating RNA exon editing as a major emerging genetic medicine modality. What Happened The platform uses a…
